NEW YORK, June 5, 2015 /PRNewswire/ — Yesterday’s FDA Advisory Committee recommendation for the approval of flibanserin was a landmark step for women’s health, addressing the important unmet medical need for women living with hypoactive sexual desire disorder, or HSDD.…
Activity of Lorexys Requires Precise Ratio of Active Components, Trazodone and Bupropion JERSEY CITY, N.J., July 29, 2013 — S1 Biopharma, Inc., a developer of first-in-class drugs for sexual dysfunction in women and men, today announced enrollment and dosing of premenopausal…
60-Patient National Phase I-b Clinical Trial to Begin in 2012 Jersey City, NJ — February 20, 2012 — S1 Pharmaceuticals, Inc. (S1) announced today that it has submitted its Investigational New Drug (IND) application to the U.S. Food and Drug…